Citations

Showing 10 of 108083 citations.

Physical activity levels and hepatic steatosis: A longitudinal follow‐up study in adults
Gerage, Aline Mendes , Ritti‐Dias, Raphael Mendes , Balagopal, Prabhakaran , Conceição, Raquel , Umpierre, Daniel , Cucato, Gabriel Grizzo , Bittencourt, Márcio Sommer , Balagopal, P Babu , Conceição, Raquel Dilguerian de Oliveira , Santos, Raul D , Bittencourt, Márcio Sommer , Santos, Raúl D.

Mayo Clinic

Journal of Gastroenterology and Hepatology | August 31, 2017 | Volume: 33 | Issue: 3 | Pages: 741-746

10.1111/jgh.13965 | PMID 28857324 Get It

AbstractBackground and AimThis study aimed to evaluate the impact of physical activity (PA) on the course of hepatic steatosis (HS) in adults.MethodsHepatic steatosis status (ultrasonography) and PA levels were evaluated in 5860 subjects at baseline and after approximately 2.5 years (range: 19–50 months). At follow up, possible exposures to different PA levels were those who remained inactive, became inactive, became active, and remained active. After follow up, subjects were then classified according to the four possible states (outcomes): “remained without HS,” “developed HS” (subjects without HS at baseline), “remained with HS,” or “reverted HS.”ResultsAfter multivariate adjustments, individuals without HS that became or remained physically active were less likely to develop HS compared with those who remained physically inactive (odds ratio = 0.75, P = 0.04 and 0.75, P = 0.03, respectively). Among those with HS at baseline, becoming and remaining physically active beneficially improved the HS status (odds ratio = 0.64, P = 0.01 and 0.66, P = 0.01, respectively). However, the significance was lost when adjusted for changes in body mass index.ConclusionHigher levels of PA were associated with prevention and treatment of HS, with evidence of effect mediation by changes in body mass index.
Relationships of Clinical and Computed Tomography-Imaged Adiposity with Cognition in Middle-Aged and Older African Americans
Parker, Kirby G., Lirette, Seth T. , Deardorff, David S, Bielak, Lawrence F. , Peyser, Patricia A. , Carr, J. Jeffrey , Terry, James G. , Fornage, Myriam , Benjamin, Emelia J. , Griswold, Michael , Windham, B. Gwen , Turner, Stephen T. , Benjamin, Emelia J , Mosley, Thomas H. , Terry, James G , Lirette, Seth

Mayo Clinic

The Journals of Gerontology: Series A | August 31, 2017 | Volume: 73 | Issue: 4 | Pages: 492-498

10.1093/gerona/glx163 | PMID 28958070 Get It

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders
Schmidt, Felix , López, Reydmar , Arango, J.A. Jiménez, Paul, Friedemann , Wingerchuk, Dean M. , Greenberg, Benjamin , Kim, Ho Jin , Levy, Michael , Levy, Michael , Greenberg, Benjamin M , Paul, Friedemann , Mealy, Maureen A. , Kim, Su‐Hyun

Mayo Clinic

Multiple Sclerosis Journal | August 31, 2017 | Volume: 24 | Issue: 13 | Pages: 1737-1742

10.1177/1352458517730131 | PMID 28857723 Get It

Background: Debate exists about whether neuromyelitis optica spectrum disorder seronegative disease represents the same immune-mediated attack on astrocytic aquaporin-4 as in seropositive disease. Objective: We investigated whether response to common treatments for neuromyelitis optica spectrum disorder differed by serostatus, as assessed by change in annualized relapse rate. Methods: We performed a multicenter retrospective analysis of 245 patients with neuromyelitis optica spectrum disorder who were treated with either rituximab or mycophenolate mofetil as their first-line immunosuppressive treatment for disease prevention. Patients were followed for a minimum of 6 months following treatment initiation. Results: In those started on rituximab, the pre-treatment annualized relapse rates for seropositive and seronegative patients were 1.81 and 1.93, respectively. On-treatment annualized relapse rates significantly declined to 0.32 (seropositive; p < 0.0001) and 0.12 (seronegative; p = 0.0001). In those started on mycophenolate mofetil, the pre-treatment annualized relapse rates for seropositive and seronegative patients were 1.79 and 1.45, respectively. On-treatment annualized relapse rates declined to 0.29 (seropositive; p < 0.0001) and 0.30 (seronegative; p < 0.005). Conclusion: In this international collaboration involving a large number of neuromyelitis optica spectrum disorder patients, treatment was effective regardless of serostatus. This suggests that treatment should not differ when considering these treatments.
Direct oral anticoagulant medications in calciphylaxis
King, Brian J., McEvoy, Marian T., Shields, Raymond C., McBane, Robert D. , McCarthy, James T. , Davis, Mark D.P. , El-Azhary, Rokea A, McBane, Robert , el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | August 31, 2017 | Volume: 56 | Issue: 10 | Pages: 1065-1070

10.1111/ijd.13685 | PMID 28856671 Get It

AbstractBackgroundRecent studies suggest that calciphylaxis is a thrombotic condition in which arteriolar thrombosis leads to painful skin infarcts and consequent morbidity and mortality. Paradoxically, warfarin is implicated as a risk factor for calciphylaxis. Our objective is to report the use of oral direct thrombin and factor Xa inhibitors (termed direct oral anticoagulants [DOACs]) in patients with calciphylaxis.MethodsWe retrospectively reviewed records of 16 patients with calciphylaxis who received concomitant administration of novel anticoagulants. Patient data, including demographics, comorbidities, other treatments, and adverse events, were abstracted from the health records.ResultsEleven patients (69%) had chronic kidney disease (stage ≥3A), and eight (50%) received dialysis. Apixaban was the most frequently used agent (n = 11 [69%]). Dabigatran (n = 4 [25%]) and rivaroxaban (n = 2 [13%]) were reserved for patients with mild renal impairment (stage ≤2). One clinically relevant but nonmajor bleeding event occurred. There were no major bleeding events. Nine patients (56%) were alive at last follow‐up, and five (31%) had complete resolution of their calciphylaxis (mean follow‐up, 523 days; range, 26–1884 days).ConclusionDOACs were safe and well tolerated in patients with calciphylaxis, in this initial experience. Several patients had improvement or resolution of calciphylaxis in response to therapy that included DOACs. The degree of renal impairment should guide DOAC choice. Randomized trials are required to determine treatment efficacy.
Encephalopathy caused by novel mutations in the CMP‐sialic acid transporter, SLC35A1
Ng, Bobby G. , Asteggiano, Carla , Kircher, Martin , Buckingham, Kati J. , Raymond, Kimiyo , Nickerson, Deborah A. , Bamshad, Michael J. , Ensslen, Matthias, Blue, Elizabeth , Shendure, Jay , Freeze, Hudson H. , Ng, Bobby G

Mayo Clinic

American Journal of Medical Genetics Part A | August 31, 2017 | Volume: 173 | Issue: 11 | Pages: 2906-2911

10.1002/ajmg.a.38412 | PMID 28856833 Get It

Transport of activated nucleotide‐sugars into the Golgi is critical for proper glycosylation and mutations in these transporters cause a group of rare genetic disorders termed congenital disorders of glycosylation. We performed exome sequencing on an individual with a profound neurological presentation and identified rare compound heterozygous mutations, p.Thr156Arg and p.Glu196Lys, in the CMP‐sialic acid transporter, SLC35A1. Patient primary fibroblasts and serum showed a considerable decrease in the amount of N‐ and O‐glycans terminating in sialic acid. Direct measurement of CMP‐sialic acid transport into the Golgi showed a substantial decrease in overall rate of transport. Here we report the identification of the third patient with CMP‐sialic acid transporter deficiency, who presented with severe neurological phenotype, but without hematological abnormalities.
Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia
Stamatović, Ljiljana, Vasović, S., Trifunovic, J. , Boskov, Nedeljka, Gajić, Zoran , Parezanovic, A., Icevic, M., Ćirković, Andja , Milić, Nataša , Milic, N

Mayo Clinic

Psycho-Oncology | August 31, 2017 | Volume: 27 | Issue: 2 | Pages: 576-582

10.1002/pon.4551 | PMID 28857314 Get It

Abstract Objective Streamlining the diagnosis is a key factor in improving the treatment outcomes for breast cancer. The aim of this study was to determine factors influencing time to seeking medical advice and treatment onset in women who are diagnosed with breast cancer in Serbia. Methods The study was a multicenter, cross‐sectional national survey, performed at 10 oncology centers in Serbia. Time intervals spent throughout the complex diagnostic pathway were evaluated using a validated questionnaire administered to women with breast cancer ( n = 800). Total interval (TI) was determined using predefined time scales, including one referring to patient interval (PI), and several related to health care system interval (SI). Results Mean PI, SI, and TI were 4.5, 9.2, and 12.9 weeks, respectively; 20% of patients had a PI>12 weeks. Based on the multivariate regression model, longer PI was associated with perceived lack of time and personal disregard or trivialization of detected symptoms and signs. Women who were supported by family members or friends and had at least a secondary level education tended to have a shorter PI. Longer PI was correlated with a longer SI, while regular self‐examination, having been diagnosed by an oncologist, and living in a major city were associated with shorter SI. Conclusions Several factors, related to psychological, demographic, behavioral, and health system characteristics, determined both the time to seeking medical advice and treatment onset for breast cancer. These findings support review and refining of national strategies and policies to promote early detection, diagnosis, and treatment of breast cancer.
Improved Assessment of Chest pain Trial (IMPACT): assessing patients with possible acute coronary syndromes
Cullen, Louise , Greenslade, Jaimi , Hammett, C., O’Kane, Shanen, Ryan, Kimberley , Schluter, Jessica, Dalton, Emily , Than, Martin , Jaffe, Allan S. , O’Rourke, Peter , Parsonage, William , Jaffe, Allan, Cullen, Louise , Hawkins, Tracey Vann , Parker, Kate , Brown, Anthony FT , Peacock, William Frank , Jaffe, Allan S. , Than, Martin

Mayo Clinic

Medical Journal of Australia | August 31, 2017 | Volume: 207 | Issue: 5 | Pages: 195-200

10.5694/mja16.01351 | PMID 28987132 Get It

Technical Aspects of Contrast-enhanced MR Angiography: Current Status and New Applications
Riederer, Stephen J. , Stinson, Eric G. , Weavers, Paul T.

Mayo Clinic

Magnetic Resonance in Medical Sciences | August 30, 2017 | Volume: 17 | Issue: 1 | Pages: 3-12

10.2463/mrms.rev.2017-0053 | PMID 28855470 Get It

Continuum of disease versus the fascination with numbers: an ongoing struggle
Pislaru, Sorin V. , Pellikka, Patricia A. , Sabbah, Michael S. , Pellikka, Patricia A

Mayo Clinic

Heart | August 30, 2017 | Volume: 104 | Issue: 3 | Pages: 188-189

10.1136/heartjnl-2017-311936 | PMID 28855270 Get It

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Northfelt, Don W., Mahr, Michael A. , Ralya, Andrew T., Kuffel, Mary J., Buhrow, Sarah A. , Safgren, Stephanie L. , McGovern, Renee M., Black, John L. , Dockter, Travis , Haddad, Tufia C. , Erlichman, Charles , Adjei, Alex A. , Visscher, Dan W., Kipp, Benjamin R. , Liu, Minetta C. , Hawse, John R. , Doroshow, James H. , Collins, Jerry M. , Streicher, Howard , Ames, Matthew M. , Élez, Elena , Reid, Joel M. , Kuffel, Mary, Black, John, Haddad, Tufia, Visscher, Dan, Chalmers, Zachary R, Frampton, Garrett, Ingle, James N. , Safgren, Stephanie L , Goetz, Matthew P. , Suman, Vera J. , Chalmers, Zachary Rockow , Frampton, Garrett M. , Elez, Elena

Mayo Clinic

Journal of Clinical Oncology | August 30, 2017 | Volume: 35 | Issue: 30 | Pages: 3391-3400

10.1200/jco.2017.73.3246 | PMID 28854070 Get It

Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estrogen receptor–positive metastatic breast cancer. An accelerated titration schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 design and expansion at 40, 80, and 100 mg per day. Tumor DNA from serum (circulating cell free [cf); all patients] and biopsies [160 mg/day and expansion]) was sequenced. Results Of 41 enrolled patients, 38 were evaluable for MTD determination. Prior endocrine regimens during which progression occurred included aromatase inhibitor (n = 36), fulvestrant (n = 21), and tamoxifen (n = 15). Patients received endoxifen once daily at seven dose levels (20 to 160 mg). Dose escalation ceased at 160 mg per day given lack of MTD and endoxifen concentrations > 1,900 ng/mL. Endoxifen clearance was unaffected by CYP2D6 genotype. One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus). Overall clinical benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (95% CI, 13.4% to 43.1%) including prior tamoxifen progression (n = 3). cfDNA mutations were observed in 13 patients ( PIK3CA [n = 8], ESR1 [n = 5], TP53 [n = 4], and AKT [n = 1]) with shorter progression-free survival ( v those without cfDNA mutations; median, 61 v 132 days; log-rank P = .046). Clinical benefit was observed in those with ESR1 amplification (tumor; 80 mg/day) and ESR1 mutation (cfDNA; 160 mg/day). Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53, and AKT) were undetected by cfDNA, whereas cfDNA mutations ( ESR1, TP53, and AKT) were undetected by biopsy. Conclusion In endocrine-refractory metastatic breast cancer, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising antitumor activity.